Latest Breaking News On - Jeffreyv matous - Page 1 : comparemela.com

Dr Matous on Factors Influencing Treatment Selection and Sequencing in Multiple Myeloma

Jeffrey V. Matous, MD, discusses factors to be considered when determining the optimal sequencing of bispecific antibodies in multiple myeloma.

United statesJeffreyv matousUniversity of colorado health sciences centerColorado blood cancer instituteColorado health sciences centerMultiple myelomaCart cell therapyBispecific antibodies

Teclistamab Plus Nirogacestat Elicits Durable Responses in Relapsed/Refractory Myeloma

Teclistamab Plus Nirogacestat Elicits Durable Responses in Relapsed/Refractory Myeloma
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United statesJeffreyv matousUniversity of coloradoColorado blood cancer instituteInternational staging system

Dr Matous on the Future Directions of CAR T-Cell Therapy in Multiple Myeloma

Jeffrey V. Matous, MD, discusses future directions of CAR T-cell therapy in multiple myeloma, highlighting the potential promise of novel targets beyond BCMA.

United statesJeffreyv matousUniversity of colorado health sciences centerColorado blood cancer instituteColorado health sciences centerMultiple myelomaOnclive tvCart cell therapy

Dr Matous on Ongoing Multiple Myeloma Clinical Trials at the University of Colorado Health

Jeffrey V. Matous, MD, discusses upcoming and ongoing clinical trials in multiple myeloma being conducted at the University of Colorado Health Sciences Center.

United statesJeffreyv matousUniversity of colorado health sciences centerColorado blood cancer instituteColorado health sciences centerColorado health sciencesUniversity of colorado cancer center nci designated comprehensiveMultiple myelomaOnclive tv

Dr Matous on the Benefit Derived from the IKEMA Trial in R/R Multiple Myeloma

Jeffrey V. Matous, MD, discusses the benefit derived from the phase 3 IKEMA trial in patients with relapsed/refractory multiple myeloma, highlighting the key factors to take into account when evaluating patients for relapsed/refractory disease within this treatment space.

United statesJeffreyv matousUniversity of colorado health sciences centerColorado blood cancer instituteColorado health sciences centerUniversity of colorado cancer center nci designated comprehensiveOnclive tvMultiple myeloma